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Objective: Central vein stenosis or occlusion remains an unfortunate complication associated with the use of dialysis
catheters. In patients with a functioning arteriovenous ﬁstula, central vein stenosis can lead to debilitating arm, breast, or
neck swelling. Treatment typically involves central vein angioplasty or stenting, or both, but restenosis and reocclusion
rates remain high. Presented here are the initial results of a unique series of patients with a mature arteriovenous access
and symptomatic upper extremity venous hypertension who were treated with axillary vein-to-femoral vein bypass after
endovascular therapy failed.
Methods: This was a retrospective analysis of 10 hemodialysis patients with a functioning right upper extremity access who
underwent axillary vein-to-femoral vein bypass between December 2011 and April 2013.
Results: The 10 patients (seven men) were a median age of 58 years. All patients had documentation of prior central
venous catheter placement and had undergone a previous endovascular procedure that was unsuccessful or technically
unfeasible. The median hospital stay was 2 days (range, 1-3 days), and the median assisted-primary patency was 197 days
(25th-75th percentile, 114-240 days). Three patients presented with recurrent arm swelling that was successfully
managed in one patient with revision of the proximal anastomosis. Three additional patients presented with subsequent
lower extremity swelling, with one patient beneﬁtting from femoral vein angioplasty. Ultimately, six patients continued to
use their original access, and two required placement of interval central venous catheters for hemodialysis.
Conclusions: In patients who have exhausted all endovascular options, axillary-to-femoral vein bypass may represent a safe
and efﬁcacious approach to alleviate extremity swelling while simultaneously salvaging a functional dialysis access. (J Vasc
Surg 2014;59:1651-6.)Despite concerted efforts to promote placement of
autogenous arteriovenous ﬁstulas (AVFs) before the
commencement of dialysis, the rate of central venous cath-
eter (CVC) use in the ﬁrst 90 days of initial treatment is still
surprisingly high, at nearly 80%.1,2 Therefore, catheter-
associated central vein stenosis or occlusion remains a
pervasive and troubling complication.2 The discussion is
not trivial: multiple studies have demonstrated a clear sur-
vival beneﬁt, a decrease in hospitalization rates, and a sub-
stantial reduction in overall health care costs in individuals
who are able to use AVFs for hemodialysis (HD).3-5
The correlation between CVC use and central vein
stenosis has been well documented in multiple series
and affects up to half of all patients with a history of
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://dx.doi.org/10.1016/j.jvs.2013.12.042alarmingly high, is most likely an underestimation of the
true incidence of this condition because central vein steno-
sis is often clinically unrecognizable in most patient
populations.
In the HD-dependent demographic, central vein ste-
nosis typically manifests as extremity swelling, breast
engorgement, and prominent superﬁcial veins ipsilateral
to a functioning ﬁstula or graft.7,8 Although the pathogen-
esis of this condition is multifocal, the recurrent trauma
from CVC placement and the inﬂammatory milieu that en-
sues results in a cascade of cellular events that undoubtedly
culminate in venous thrombosis or cicatrix and, ultimately,
central vein occlusion.9,10
Given the importance of reliable vascular access in HD
patients, central vein disease presents a challenging prob-
lem to the vascular surgeon. Once the stenosis progresses
to frank obstruction, maintaining a functional AVF be-
comes problematic.11 To salvage the ﬁstula, percutaneous
transluminal angioplasty is routinely used and is often com-
bined with stent deployment; however, the durability of
endovascular intervention is less than desirable. This has
forced surgeons to search for alternative solutions to
manage central vein stenosis and its associated clinical im-
plications. Presented here are the initial results of a unique
series of patients with a mature arteriovenous access and
symptomatic upper extremity venous hypertension who
were treated with axillary vein-to-femoral vein bypass after
endovascular therapy failed.1651
Table. Patient demographics, postoperative complications, and subsequent interventions
Pt
Age,
years
Degree of
central stenosis
Assisted
primary
patency, days
AF volume
ﬂow,
mL/min Complications
Subsequent
interventions
Original
dialysis access
Ultimate
dialysis access
1 56 Right subclavian
vein to distal
brachiocephalic
vein
292 220 Dilatation of
ﬁstula; lower
extremity
swelling
Plication/ligation
of ﬁstula; iliac
vein stent
Basilic
transposition
AVF
Contralateral
(nondominant)
radiocephalic
ﬁstula
2 82 Distal
brachiocephalic
vein to proximal
SVC
177 NR Thrombosis of
AF bypass with
recurrent arm
swelling
Failed
thrombectomy/
AF bypass
revision
Radiobrachial
AVF
Lower leg loop
AVG using
6-mm PTFE
3 66 Proximal right
subclavian vein
and entirety of
brachiocephalic
vein
240 2129 Recurrent upper
extremity
swelling
Revision of axillary
anastomosis
Basilic
transposition
AVF
Original access
4 54 Right subclavian
vein to distal
brachiocephalic
vein
96 1300 None None Basilic
transposition
AVF
Original access
5 42 Right subclavian
vein
162 1929 Lower extremity
swelling;
infection of AVG
Excision of
infected AVG
bypass; CVC
placement
Axillobrachial
AVG
Femoral catheter
6 76 Right subclavian
vein
219 457 Lower extremity
swelling
Femoral vein
angioplasty
Basilic
transposition
AVF
Original access
7 42 Right subclavian
vein to proximal
brachiocephalic
vein
216 300 Superﬁcial wound
infection
Antibiotic therapy Basilic
transposition
AVF
Original access
8 52 Right subclavian
vein and entirety
of
brachiocephalic
vein
57 NR Thrombosis and
infection of AF
bypass
Removal of AF
bypass and CVC
placement
Basilic
transposition
AVF
Femoral catheter
9 66 Left subclavian vein 432 NR None None Brachiocephalic
AVF
Original access
10 43 Right subclavian
vein
114 NR None None Axillobrachial
AVG
Original access
AF, Axillary-to-femoral vein bypass; AVG, arteriovenous graft; AVF, arteriovenous ﬁstula; CVC, central venous catheter; NR, not recorded; Pt, patient; PTFE,
polytetraﬂuoroethylene; SVC, superior vena cava.
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This was a retrospective analysis of 10 HD patients with
functioning right upper extremity access who underwent
axillary vein-to-femoral vein bypass between December
2011 and April 2013. The appropriate clearance was ob-
tained for this study from our ongoing Institutional Review
Board-approved clinical database. Indications for venous
bypass included upper extremity swelling in seven patients
and a combination of breast and upper extremity swelling
in three patients.
Surgical technique. The operation was performed un-
der general anesthesia in all 10 patients. In this series, an
axillary incision had been used to access the vein. Most
recently, an infraclavicular incision was used because two
episodes of graft kinking occurred in the ﬁrst 10 patients.
Regardless of the approach, the axillary and ipsilateral com-
mon femoral veins were circumferentially dissected free.
After systemic heparinization, an 8- or 10-mm ringedexpanded polytetraﬂuoroethylene (ePTFE) graft was sewn
to the axillary vein, tunneled along the lateral chest wall
through a counter incision, and then anastomosed to the
femoral vein.
Postoperative follow-up. Once discharged, the initial
follow-up appointment was scheduled 2 to 3 weeks after
surgery. After all of the incisions were healed, duplex scans
of the graft and ﬁstula were performed to demonstrate
patency of the bypass. Phone interviews were conducted
with patients who had not had recent follow-up to assess
their clinical status. Assisted primary patency, which rep-
resents the absolute duration of patency from the time of
bypass (including any interventions), was recorded for all
patients in the study.
RESULTS
The 10 patients (seven men) in this study were a me-
dian age of 58 years (range, 42-82 years). The etiology
Fig 1. Time to ﬁrst intervention after axillary-to-femoral vein
bypass.
Fig 2. Time to new hemodialysis (HD) access placement.
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diabetes in 2, lupus nephritis in 2, and focal segmental glo-
merulosclerosis in 1. All patients had documentation of
prior CVC placement and all had undergone at least one
endovascular procedure that was unsuccessful or technically
unfeasible. The operations were performed without in-
hospital morbidity or death, and the median duration of
admission was 2 days (range, 1-3 days). The pre-existing
AVFs were used for immediate postoperative HD without
incident in all patients.
Right upper extremity or breast swelling, or both was
noticeably improved in all 10 patients at the their initial
follow-up; however, recurrent arm enlargement was appre-
ciated in three patients after varying periods of time. This
was successfully remedied in patient 3 by revising the prox-
imal anastomosis. The other two patients underwent a
failed thrombectomy (patient 2) and graft removal due to
systemic infection (patient 8). Three additional patients
experienced lower extremity swelling after their bypass
was created. Symptomatic resolution was achieved in pa-
tient 6 through femoral vein angioplasty. Patient 1 had a
high-volume ﬁstula and a widely patent iliac vein stent ipsi-
lateral to the axillary-to-femoral vein bypass. Despite initial
plication of the ﬁstula, his lower extremity swelling per-
sisted and, ultimately, the ﬁstula was ligated. Fortunately,
he beneﬁtted from formation of a contralateral radioce-
phalic ﬁstula distal to a known central vein occlusion, and
swelling has not developed in that arm. Lastly, an arterio-
venous graft infection developed in patient 5 that necessi-
tated access excision.
The median assisted primary patency and overall
follow-up for the cohort were 197 days (25th-75th percen-
tile: 114-240 days) and 207 days (range, 114-432 days),
respectively. Six of the 10 patients were able to maintain
their original access for dialysis, two underwent CVC place-
ment, and new arteriovenous graft/AVFs were created in
two. The assisted primary patency also represents the dura-
tion of access functionality since bypass placement. The
Table presents a more detailed overview of each patient’spostoperative course. Figs 1 and 2 illustrate time to ﬁrst
intervention and time to new dialysis access placement,
respectively.
DISCUSSION
Although the prevalence of AVFs for dialysis access has
been increasing, the placement of CVCs still persists at un-
acceptably high rates. Unfortunately, as a result of this
practice, the occurrence of central vein stenosis continues
to plague the HD patient and surgeon, alike. This conun-
drum has encouraged vascular surgeons to devise novel
therapies to not only alleviate the clinical sequelae of cen-
tral vein occlusion but also salvage the ipsilateral AVF.
Endovascular therapies are the initial treatment for cen-
tral vein stenosis or occlusion. Access is usually obtained
through the ﬁstula, but additional femoral access is occa-
sionally necessary when the stenosis or occlusion is difﬁcult
to cross with a wire. Although the immediate results of
balloon angioplasty of central veins provides relief of ex-
tremity swelling, while at the same time maintaining the ﬁs-
tula, the results tend to be short-lived, with restenosis and
reocclusion being common.12-14 Previous reports have
documented 1-year primary patency rates between 10%
and 40% with angioplasty alone.13-15 The addition of stent
deployment to mere balloon angioplasty has added little to
long-term patency rates.16
The most deﬁnitivedbut simultaneously drasticd
surgical remedy is ligation of the access.17 This has the
obvious consequence of abolishing an otherwise func-
tioning ﬁstula in a demographic with limited alternative op-
tions. As seen in this series, all but one patient was treated
for right-sided issues, the nondominant left arm having
already been exhausted of options for access. However, as
seen in one patient in this series and previously reported
elsewhere, an overlooked forearm cephalic or basilic vein
distal to a prior failed upper arm access and central vein oc-
clusion can be successfully used for a wrist ﬁstula without
concomitant swelling.18,19 Lastly, reducing the ﬂow in
large AVFs by using one of several reported plication
Fig 3. Flowchart illustrates the algorithmic approach to patients
with symptomatic central vein occlusion. In patients with true central
vein occlusion, surgical bypass is considered only after percutaneous
therapy and ﬁstula plication (if applicable) have been attempted.
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swelling.20-22
Surgical bypass offers an additional avenue for interven-
tion, and multiple studies have demonstrated reasonable
long-term patency rates with a minimal effect on overall
morbidity. Several conﬁgurations to circumvent the area
of occlusion have been investigated, and include bypasses
to the right atrium, ipsilateral internal jugular vein, and
ipsilateral external jugular vein.23-28 These extra-anatomic
bypasses have limited application if the area of interest in-
volves the junction of the subclavian and jugular veins or
if the brachiocephalic vein or superior vena cava are
involved. Although right atrial bypass is effective in evading
occlusions, it is a large undertaking in a population of pa-
tients with a myriad of comorbidities.
Uncommonly, extra-anatomic bypass to the lower ex-
tremity has been used to palliate the symptoms of malig-
nant superior vena cava syndrome. Long-term data are
limited, however, due to the aggressive oncologic nature
of the disease process.29,30 In the dialysis population,
Kavallieratos et al31 reported eight patients who underwent
ipsilateral axillary-to-saphenous vein bypass with PTFE for
symptomatic central vein occlusion. The 6-month patency
rate was 87.5%, and all patients experienced symptomatic
improvement of their swelling.31
Because our institution is a busy tertiary dialysis access
referral center, central vein issues are not uncommon in our
patient population. Initially, an endovascular approach with
angioplasty is our routine, with stenting having largely
been abandoned. This series describes our initial experience
with patients undergoing axillary-to-femoral venous bypass
for recurrent symptomatic central vein stenosis or occlusion
after failed interventional procedures. The median assisted
primary patency rate, at the time of publication, was
197 days (range, 57-432 days), with six patients still
beneﬁting from patent axillary-to-femoral vein bypasses.
Given the limitations of previous interventions in providing
a durable solution to mitigating central vein issues, the out-
comes in our cohort are encouraging. As the experience
with this technique grows, we hope improvements in its
execution will result in consistently sustainable long-term
patency (Fig 3 provides an algorithmic approach to central
vein stenosis).
As is typical of any patient who has required dialysis for
a prolonged period of time, speciﬁcs regarding the exact
number of CVCs placed and endovascular interventions
performed can be difﬁcult to ascertain. Postoperatively,
lower extremity swelling developed in several patients in
this series, presumably due to unknown venous abnormal-
ities, most likely from prior catheterization. Therefore, a
ﬁstulogram and ileofemoral venogram are performed at
the beginning of the operation under local anesthetic.
Once favorable anatomy is conﬁrmed, general anesthesia
with a laryngeal mask airway or an endotracheal tube is
induced.
Two technical factors have evolved during our experi-
ence with this procedure. Although ring-reinforced ePTFE
is the obvious choice for the bypass, the diameter usedshould vary according to the nature of the arm access. In
patients with large ﬁstulas, an 8-mm graft may not relieve
the venous hypertension, and thus, a 10-mm graft is rec-
ommended. If the arm access consists of an ePTFE graft,
then an 8-mm axillary-to-femoral bypass will typically suf-
ﬁce. In addition, the access for the proximal anastomosis
in this series was obtained through an axillary incision.
Two patients, however, required surgical revision for kink-
ing of the graft at that site that caused recurrent arm
edema. Although a transaxillary approach is technically
easier, an infraclavicular approach, with tunneling deep to
the pectoralis minor muscle, will prevent this complication.
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tients after surgical bypass, we have considered the use of
systemic anticoagulation in the postoperative setting.
Before axillary-to-femoral vein bypass, four patients had
been treated with therapeutic warfarin for other comorbid
conditions, whereas three were receiving aspirin therapy.
Interestingly, both patients who were discovered to have
thrombosed PTFE bypasses had been treated preoperatively
with warfarin and had continued their anticoagulation post-
operatively. To date, no published, randomized-controlled
trials have been conducted to demonstrate the efﬁcacy of
systemic anticoagulation in preventing PTFE throm-
bosis.32 The bleeding risk associated with systemic anti-
coagulation in patients with end-stage renal disease is
not trivial, and therefore, we do not initiate this therapy
in all of our patients after bypass. Instead, we support
aspirin therapy if no contraindications exist and selective
administration of warfarin only in those with docu-
mented hypercoagulable states or a history of previous
graft thrombosis.33
CONCLUSIONS
Successful palliation of the symptoms of central vein
stenosis or occlusion in the dialysis patient is a challenging
problem. Percutaneous intervention is clearly the treatment
of ﬁrst choice due to its simplicity and low morbidity.
However, in patients who have exhausted all endovascular
options, axillary-to-femoral vein bypass represents a unique
and relatively safe approach to alleviate extremity swelling
while salvaging a functional dialysis access.
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